drugset / Trial / NCT06120530

Intraperitoneal Bupivacaine for Pelvic Organ Prolapse

NCT06120530 ↗

Phase 4 Completed 91 enrolled Indiana University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effects of 30 mL intraperitoneal Bupivacaine without epinephrine 0.25% on postoperative pain control in patients undergoing pelvic organ prolapse repair. The investigators hypothesize that use of intraperitoneal Bupivacaine will decrease postoperative pain scores and opiate consumption in the postoperative period, following pelvic organ prolapse repair.

Timeline

Start
2023-08-16
Primary completion
2024-03-15
Completion
2024-03-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified 30 mg Other

Indications